UNDERWRITING AGREEMENT between LIRUM THERAPEUTICS, INC. and THINKEQUITY LLC as Representative of the Several Underwriters LIRUM THERAPEUTICS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • March 11th, 2024 • Lirum Therapeutics, Inc. • Pharmaceutical preparations • New York
The undersigned, Lirum Therapeutics, Inc., a corporation formed under the laws of the State of Delaware (collectively with its affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being an affiliate of Lirum Therapeutics, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with ThinkEquity LLC (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as set forth below.
SECOND AMENDMENT TO THE LICENSE AGREEMENTLicense Agreement • March 11th, 2024 • Lirum Therapeutics, Inc. • Pharmaceutical preparations
This Second Amendment to the License Agreement (this “Second Amendment”) is made and entered into this 11th day of July 2023, by and among IGF Oncology, LLC, a Delaware limited liability company (“IGF”), and Lirum Therapeutics, Inc., a Delaware corporation (“LIRUM”). IGF and LIRUM are from time to time referred to herein individually as a “Party” or collectively as the “Parties”.
